Pono paha ka heluna kanaka i hoʻopaʻa ʻia i ka maʻi maʻi COVID-19

Curtis J. Mea maʻi webinar: COVID-19 kano a me ka lapaʻau. ʻŌlelo: Rheumatism Research Foundation. Mei 11, 2021 (Nīnau Manaʻo Virtual).
Curtis J. Mea maʻi webinar: COVID-19 kano a me ka lapaʻau. ʻŌlelo: Rheumatism Research Foundation. Mei 11, 2021 (Nīnau Manaʻo Virtual).
Ua ʻōlelo ʻo Jeffrey R. Curtis, MD, ka luna o ka COVID-19 Vaccine Clinical Guidance Working Group o ka American Academy of Rheumatology, ʻo ka poʻe maʻi immunosuppressed "pono" e hoʻohana mau i nā mea hoʻoikaika kino COVID-19 i ka wā e hiki mai ana.
Ua haʻi aku ʻo Curtis, he rheumatologist, epidemiologist, a me ke kaukaʻi o ka lāʻau lapaʻau ma ke Kulanui o Alabama ma Birmingham, i ka poʻe i hele mai i kahi hanana Q&A hou i mālama ʻia e ka Rheumatology Research Foundation e manaʻoʻiʻo nei ʻo ia e lilo i mea maʻamau i kēia mau maʻi.
“ʻOiaʻiʻo, nui ka ʻepekema, a ke ulu mau nei ka ʻepekema. ʻO nā mea a pau āu e manaʻo ai i kēia mahina, ʻokoʻa paha ka mahina aʻe, no laila, manaʻo wau i nā mea āpau a mākou e ʻōlelo ai a kamaʻilio paha e pili ana i kēia pō, e loli paha ia, "i ʻōlelo ai ʻo Curtis i ka poʻe i hele ma ka hui virtual. "Ke manaʻo nei au pono paha nā kānaka i nā mea hoʻoikaika. ʻAʻole paha ia ka hihia no nā mea a pau, akā manaʻo wau he mea maʻamau ka loaʻa ʻana o ka booster a laila hana i kēlā me kēia manawa. Hiki ke hoʻopau ʻia e like me ka maʻi maʻi flu, inā ʻaʻole i kēlā me kēia makahiki, a laila pono ʻoe i kēlā me kēia makahiki.
Ua hoʻohui ʻo ia e pili ana i ka mālama ʻana i ka mea maʻi, ʻoi aku ka maikaʻi o ka poʻe i ka pōmaikaʻi mai ka booster immunizations a i ʻole ka hana hou ʻana o nā maʻi.
"Ua hāpai kekahi i ke kamaʻilio ʻana i ke kūlana ʻaʻole paha lākou i ka maʻi a i ʻole ke kano a lākou i makemake ai, no laila e pili ana i ka mālama ʻana i loaʻa iā ʻoe, he mea kēia e kūkākūkā ai me kāu mea mālama olakino," wahi a Curtis. "Akā ke manaʻo nui nei au he nani paha ka manaʻo o nā boosters."
I ka nīnau ʻana e pili ana i nā manaʻo o ka hoʻohana ʻana i ka lāʻau lapaʻau ʻo Pfizer a i ʻole Moderna me kahi mea hoʻonui o kahi hui ʻē aʻe, ua pane ʻo Curtis ua manaʻo ʻo ia e manaʻo ka poʻe loea e hoʻomau ka poʻe e hoʻohana i kēia kano ma ke ʻano he kano mua.
Ua ʻōlelo ʻo ia: "Malia paha ʻaʻole ia he haʻawina piha i ka wā e hiki mai ana." “Ua piha au i nā manaʻolana. Pono ʻoe e hoʻomau i ke kākoʻo i loaʻa iā ʻoe mai ka hoʻomaka.
Ua ʻōlelo pū ʻo Curtis i kekahi mau lāʻau rheumatic, me ka rituximab (Rituxan, Genentech) a me ka mycophenolate mofetil, hiki ke hōʻemi i ka hopena o ka kano COVID-19.
Ua ʻōlelo ʻo ia: "Manaʻo wau ʻo Rituximab kekahi o nā lāʻau lapaʻau hoihoi loa." He mea maikaʻi loa ʻo Rituximab i ka hoʻopau ʻana i nā cell B a paʻakikī i ke kino ke hana i nā antibodies. He mea maikaʻi kēia ke mālama ʻoe i kekahi mea me nā antibodies āu e makemake ai e hoʻopau, akā inā makemake ʻoe e kōkua i ka ʻōnaehana pale i ka hakakā ʻana i nā maʻi i ka wā e hiki mai ana, ʻaʻole ia he mea maikaʻi. ”
Hiki i ka Rituximab ke hoʻemi i ka pane ʻana o ka immune ma mua o nā lāʻau lapaʻau ʻē aʻe. ʻO ka Mycophenolate mofetil kekahi. "ʻO kēia nā mea ʻelua aʻu e kānalua nui ai, e hōʻoiaʻiʻo loa ua pale maikaʻi ʻia kekahi mai COVID-19."
Wahi a Curtis, nā pilikia e pili ana i ka JAK inhibitors a me ka hōʻemi ʻana i nā hopena kano, me ka ACR COVID-19 Vaccine Clinical Guidance Working Group ua hoʻokipa pū kekahi.
Ua ʻōlelo ʻo Curtis: "ʻO ia ke kumu i manaʻo ai kekahi o lākou, inā hiki, ʻoi aku ka naʻauao o ka manawa pōkole." “ʻAʻole kēia he ʻōlelo aʻo maʻamau, pono ʻoe e hana i kēia me nā koina āpau, akā me kou rumatika e kamaʻilio me ke kauka maʻi. Ua loaʻa iā ACR nā ʻōlelo aʻoaʻo hou loa mai ka hui alakaʻi alakaʻi, a ua hana maoli ʻia kēia mau ʻōlelo i loko o nā lā i hala.
Ua ʻike ʻia kahi noiʻi hou i paʻi ʻia ma Gut i ​​ka poʻe maʻi me ka maʻi ʻeha o ka ʻōpū i loaʻa i ka infliximab i hōʻemi ʻia ka pane ʻana i ka pale ʻana i ka maʻi COVID-19 ma hope koke o ka hoʻopiʻi mua ʻana (Remicade, Janssen). Eia naʻe, i ka loaʻa ʻana o ka maʻi hoʻokahi ma hope o ka lua o ka lāʻau lapaʻau, ʻike ʻia ka pane ʻana o ka immune.
Wahi a Curtis, ua hoʻolōʻihi kēia i ka manawa no ka loaʻa ʻana o ka lua no ka mālama ʻana i nā doses ma kekahi mau ʻāina, ʻaʻole wale no IBD a me infliximab, akā no nā poʻe maʻi me nā maʻi autoimmune a me nā lāʻau lapaʻau.
"Inā noho ʻoe i kahi ʻāina a ʻaʻole ʻo ʻAmelika kekahi o lākou, a laila e hoʻolōʻihi ʻia ka manawa mai ka maʻi mua a i ka lua e mālama ai i ka maʻi i hiki i nā mea āpau ke loaʻa ka maʻi mua. Manaʻo wau, ʻaʻole paha he manaʻo maikaʻi kēia no ka poʻe e hele ana i ka immunomodulatory therapy no ka maʻi o Crohn a i ʻole lupus, vasculitis, rheumatoid arthritis a i ʻole nā ​​​​maʻi ʻē aʻe. Curtis. "ʻOiaʻiʻo, ʻaʻole ia infliximab wale nō, akā ʻo Remicade a me [biosimilars] Inflectra a me Renflexis. Ke manaʻo nei hoʻi au ua like ka nui o kā mākou mau lāʻau. "
Ua hoʻohui ʻo ia i kēia manawa he nui nā noiʻi e pili ana i ka pane ʻana o nā mea maʻi me nā maʻi autoimmune i ka maʻi COVID-19 ma hope o ka mua a me ka lua. Hōʻike nā hopena e hana ʻia nā antibodies holoʻokoʻa ma hope o ka pau ʻana o ke ʻano o nā kano. pane.
Ua ʻōlelo ʻo Curtis: "ʻĀnō, aia kekahi mau haʻawina i ka palapala, aʻo lākou i ka mea e hana ma hope o ka lawe ʻana i ka maʻi mua." ʻAʻole maikaʻi ka pane ʻana o ka lāʻau o ka poʻe he nui, akā no nā poʻe he nui, ʻaʻole maikaʻi loa ka hopena. No laila, ke manaʻo nei au ʻo ka ʻike nui aʻu i aʻo ai mai kekahi o nā manuscript aʻu i loiloi ai aia i loko o ka lehulehu, a ua hoʻouna malu ʻia kekahi iaʻu, a pono ʻoe e ʻae i ka lua.
"Heʻoiaʻiʻo loa kēia inā loaʻa iā ʻoe kahi maʻi autoimmune a i ʻole e loaʻa ana i nā lāʻau lapaʻau e pili ana i ka pale ʻana, no ka mea inā ʻaʻole ʻoe e hoʻopau i nā ʻano haʻawina holoʻokoʻa e like me ka mea i manaʻo ʻia, e hoʻomau ʻia kekahi poʻe a ma mua o ka loaʻa ʻana o ka pane antibody i manaʻo ʻia. ka lua. Ua hoʻohui ʻo ia. "A laila, ma ka ʻōlelo maʻamau, ʻike ʻia nā mea maʻi me ka rumatika ma hope o ka loaʻa ʻana o ka lua, akā aia kekahi mau ʻokoʻa."

https://www.youtube.com/watch?v=-JaasdO90oM

https://www.youtube.com/watch?v=wAS7TSJrNVg